CD4 and breast cancer: Finally, our study reveals that BC patients with CD4+AC ≥451 cells/μL or CD8+AC ≥324 cells/L demonstrated a longer PFS than BC patients with CD4+AC <451 cells/μL or CD8+AC <324 cells/μL, which is consistent with our previous study [41].